OR WAIT null SECS
Transferring Energy to Hot Melt Extrusion
A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.
The use of appropriate taste-masking and appearance technologies can facilitate patient compliance.
A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.
This study reviews changes in in-country testing (registration testing, import testing) requirements and analyzes current trends.
Guidance documents and interaction with FDA can help manufacturers stay in GMP compliance, says Siegfried Schmitt, VP Technical, at Parexel.
A Closer Look at mRNA in Oncology and Vaccines
June 01, 2024
CGT Catapult will implement Cellular Origins' robotic platform in its Stevenage, UK, site to establish automated CGT manufacturing.
May 31, 2024
Sterling is strengthening its development and manufacturing services for ADCs with a dedicated GMP suite at its Wisconsin facility.
May 30, 2024
Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.
A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.
The company’s new division will provide end-to-end integrated discovery services.
At a recent INTERPHEX conference, Laura Moody (Director of Product Management, Pharma North America, Syntegon) shared some insights into current trends in the pharmaceutical industry, including the EU Annex 1.
FDA granted priority review to Sanofi's sBLA for Sarclisa in combination with VRd in treating transplant-ineligible patients who are newly diagnosed with multiple myeloma.
Bkemv (eculizumab-aeeb) is the first interchangeable biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.
May 29, 2024
The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery.